Tissue Regenix Group PLC VP, Orthopaedic, Inc. North America appointed
February 11 2016 - 2:00AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
11 February 2016
Tissue Regenix Group plc
Appointment of Vice President of Tissue Regenix Orthopaedic,
Inc. North America
York, 11 February 2016 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix") or ("The Group") the regenerative medical
devices company, is pleased to announce the appointment of Drew
Distin as Vice President ("VP") of the Group's recently established
subsidiary, Tissue Regenix Orthopaedic, Inc. North America. Drew
will commence the role as of March 1(st) 2016.
Drew is well respected within the Orthopaedic sector in the
United States having held a number of senior sales and business
development roles at Parkus Medical, LLC. Osiris Therapeutics, Inc.
Nuortho Surgical, Inc. RTI Biologics, Inc. and CryoLife, Inc.
With specialist knowledge in maximising sales through targeted
marketing, he joins Tissue Regenix as it embarks on the next stage
of commercialisation with its dCELL(R) Orthopaedic applications.
His focus will be to drive their entry into the US marketplace in
the coming years, with the first step expected to begin in
2017.
Currently, the Group have ongoing clinical trials for the
OrthoPure XM (Porcine meniscus) and OrthoPure XT (Porcine tendon)
products within the EU and aim to achieve CE mark submission by the
end of the year for XM.
In the US, it is expected that the market entry strategy will
focus on human tissue applications, initially starting with the
human tendon (OrthoPure HT). Tissue Regenix is currently in
partnership with tissue bank Community Tissue Services (CTS) for
the manufacturing of its wound care product DermaPure(R), and this
licencing model is one which the Group expects to replicate with
relevant Orthopaedic partners.
Peter Hamer, Commercial Director, Tissue Regenix Orthopaedic
Ltd, said:
"We are delighted to welcome Drew to the Orthopaedic team. He
brings with him a wealth of experience that will be advantageous
throughout the next stages of our commercialisation and the
expansion of our Orthopaedic portfolio. This is a very exciting
time for Orthopaedics at Tissue Regenix as we continue enrolment of
our OrthoPure XT clinical trial and await submission for the CE
mark with OrthoPure XM. We are on course to complete these tasks
within the timeline predicted and look forward to further expansion
into the US with Drew on board."
For more information:
Tissue Regenix Group plc Tel: 01904 567
Caitlin Pearson - Corporate Communications Officer 609
Jefferies International Ltd Tel: 020 7029
Simon Hardy / Harry Nicholas 8000
Tulchan Communications Tel: 020 7353
James Macey-White / Matt Low 4200
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADBLFFQLFFBBV
(END) Dow Jones Newswires
February 11, 2016 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2023 to Aug 2024